Comments for CBLI - Stockpickr! Your Source for Stock Ideas

Comments for CBLI

Added By	Comments	Type	Date Added
Dan Williams	I'm still in the whole on this one. Bought at 5 road it up to 13 and back down. I think I'll hold.	Love	June 05, 2008
Thomas Dibble	The market today... are you still around? I miss your comments...	Love	November 12, 2007
Boeinguy	For speculative stock, I like this health sector company. Priced low.	Love	September 29, 2007
Thomas Dibble	Looks like a strong run up antisipating the anouncement of the DOD contract. Anyone have any other catalists/ideas?	Love	September 13, 2007
superdannyd	radiation poisoning cure	Love	July 16, 2007
Thomas Dibble	Well, the market today (do you have a more conventional name?), do you have any negatives on this stock? Other than the time required to do testing and the wait for contracts to be awarded I mean. The DOD decision is due in the late summer, which is genuine governmental gibberish for the fall. I'm very impressed with your due dilligence. Tom	Love	July 15, 2007
the_market_today	Thomas, The way i see it.................... The company has many more potential compounds in the pipeline because of its ability to target drugs from the secretions of the symbiotic parasites that have evolved with our cellular structures over the last 1 million years. The company has unique intellectual property protection on numerous of these bugs. That will lead to drugs for strokes, renal failure.	Love	July 07, 2007
the_market_today	Buffalo Facility Appears State of the Art Saw this comment on another message board………The blogger commented on Gudkov's Buffalo lab and facilities as being state of the art. He noted, “I have a friend who lives in Buffalo who recently visited Andrei Gudkov's lab and CBLI's future home facility. Gudkov is now the head of cellular stress at Roswell Park Cancer Center as well as being the Chief Scientific Officer for CBLI. Roswell has a new state of the art facility that any cancer researcher would kill for. CBLI has a similar licensing arrangement with Roswell that they have with the Cleveland Clinic. CBLI gets exclusive rights to anything Gudkov is working on or collaborates on. His lab will have nearly 40 researchers working and cbli gets full benefit. In addition Gudkov is now the head of research at Roswell and it has a $125 million budget. This allows him some sway with other world class researchers in his field even though the other labs are not tied direclty to the cbli deal.	Love	July 06, 2007
the_market_today	Buffalo Facility Appears State of the Art Saw this comment on another message board………The blogger commented on Gudkov's Buffalo lab and facilities as being state of the art. He noted, “I have a friend who lives in Buffalo who recently visited Andrei Gudkov's lab and CBLI's future home facility. Gudkov is now the head of cellular stress at Roswell Park Cancer Center as well as being the Chief Scientific Officer for CBLI. Roswell has a new state of the art facility that any cancer researcher would kill for. CBLI has a similar licensing arrangement with Roswell that they have with the Cleveland Clinic. CBLI gets exclusive rights to anything Gudkov is working on or collaborates on. His lab will have nearly 40 researchers working and cbli gets full benefit. In addition Gudkov is now the head of research at Roswell and it has a $125 million budget. This allows him some sway with other world class researchers in his field even though the other labs are not tied direclty to the cbli deal. This is all in addition to the 30 plus researchers on cbli's employee list. There are very few companies with access to state of the art facilities such as this and also have a market cap below $200 million. My friend who knows an enormous amount about such due diligence was very impressed. This should provide cbli numerous opportunities to test out their cancer drugs.	Love	July 06, 2007
Thomas Dibble	Unless there is some major negative developments, it's hard to see much negative with this security. The day traraders continue to make money on good news which is frustrating but htere is a lot of favorable information to come from this company I feel. There are at least 3 drugs in the pipeline with very promising test results so far.....	Love	July 04, 2007
Thomas Dibble	Unless there is some major negative developments, it's hard to see much negative with this security. The daytreraders continue to make money on good news which is frustrating but htere is a lot of favorable information to come from this company I fee..	Love	July 04, 2007
the_market_today	Value Rich Coverage Cleveland BioLabs is featured on Value Rich (iValueRich.com) and the Spring 2007 Issue of Value Rich Magazine The article notes, “ Cleveland BioLabs is generating excitement with a potential Department of Defense Contract for its lead radiation compound, an ongoing Phase II clinical trial for its oral anti-cancer compound; and animal data on its stem cell application.” Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute.	Love	July 03, 2007
the_market_today	CBLI Gets BioTech Exposure CBLI Cited Sunday July 01,in a BioHealthInvestor.com "Interview: Investment Opportunities in Healthcare with Alan Brochstein". Alan Brochstein is a CFA with AB Analytical Services. In responding to a question, he noted, "I created a universe of stocks today with all of the U.S. based biotechs with market capitalization in excess of $50mm. It is clear why so many investors are attracted to the market, as the payoffs can be quite extreme. In fact, thus far this year, nine companies have gained in excess of 75%, including Opko Health (OPK), Celsion (CLN), Bionovo (BNVI), Onyx (ONXX), BioSante (BPA), Clevland Biolabs (CBLI), Seattle Genetics (SGEN), Biopure (BPUR) and the infamous Dendreon (DNDN)."	Love	July 02, 2007
the_market_today	Shares Headed North Again Today Shares Rebounded Friday, Gaining 2.81%; on Strong Volume of 132k Shares Traded. I noticed one blogger on another board, had his take on the recent profit taking. He was saying, “The stock made a major move over the last two weeks on the basis of the Russell rebalancing and the business week article. When the stock did not push through resistance at 11.98, it was only natural that the day traders and the people who played the Russell rebalancing sold.” The key here is that the volume has definitely picked up; as CBLI has been getting increased visibility.	Love	June 29, 2007
the_market_today	Saw this on another Board Roswell Park Boosts Life Sciences Economy BUFFALO, NY- What a banner year it has been so far for Roswell Park Cancer Institute (RPCI). Since the beginning of 2007, the Institute has announced that a highly accomplished cancer researcher and his biomedical company are relocating to Buffalo, and that RPCI laboratory discoveries have led to the creation of a new life sciences spin-off company in Buffalo. Distinguished national leader, Dr. Andrei Gudkov, joins RPCI. The world-renowned researcher is Andrei V. Gudkov, PhD, from the Cleveland Clinic, and the biomedical company is Cleveland BioLabs, Inc. – the drug discovery and development company he founded in 2003. Dr. Gudkov will assume senior leadership roles at Roswell Park and Cleveland BioLabs will partner with Roswell Park to further invigorate the biomedical environment on the Buffalo Niagara Medical Campus. The moves will bring up to 50 advanced research positions to Buffalo. “Dr. Gudkov is a pre-eminent researcher, and his company has an extensive pipeline of cancer and radioprotectant drug candidates in advanced development that hold the promise of helping patients worldwide,” according to David C. Hohn, MD, president & CEO at Roswell Park.	Love	June 28, 2007
the_market_today	The way I see it ……………… From the way I see it, the stock is just getting profit taking from the strong move over the last week. The dod has not made a decision. If they win and it could come over the summer, some suggest the stock will trade north of 50.	Love	June 28, 2007
the_market_today	The CLBI Defense Related Article in Business Week’s July 2nd Issue Definitely Increases the Company Visibility The article goes on to say, “The military may be the first customer of little-known Cleveland BioLabs for its radiation protection compound called Protectan or CBLB502. The company had responded to a Defense Dept. Request for Proposal in April. "It is likely Cleveland BioLabs will get a government contract for its product by summer's end," says Stephen Brozak of WBB Securities, who rates the stock a buy.	Love	June 26, 2007
the_market_today	Another Up Day for CBLI, with Solid Volume of Nearly 129k Shares Traded While a young Company, Cleveland BioLabs, Inc. (CBLI) has been described in the past as a Cleveland Clinic spinoff. The Cleveland Clinic Foundation, located in Cleveland, Ohio, is a not-for-profit multi-specialty academic medical center that integrates clinical and hospital care with research and education. The Cleveland Clinic was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. U.S. News & World Report consistently names The Cleveland Clinic as one of the nation’s best hospitals in its annual “America’s Best Hospitals” survey. Approximately 1,200 full-time salaried physicians at The Cleveland Clinic and Cleveland Clinic Florida represent more than 100 medical specialties and subspecialties. In 2003, patients came for treatment from every state and nearly 90 countries.	Love	June 25, 2007
walter zubelik	stock appreciation	Love	June 25, 2007
the_market_today	Shares Lift Off Today, Up 5.17% to Close at $11.40 230,855 Shares Traded Today CBLI Featured in Business Week The article goes on to say, “The military may be the first customer of little-known Cleveland BioLabs Inc. (CBLI) for its radiation protection compound called Protectan or CBLB502. The company had responded to a Defense Dept. Request for Proposal in April. "It is likely Cleveland BioLabs will get a government contract for its product by summer's end," says Stephen Brozak of WBB Securities, who rates the stock a buy. It has rocketed from 4.80 in September, when it was first featured in this column, to 10.59 on June 20. Brozak says no other product offers the same level of protection from radiation exposure. CEO Michael Fonstein says Protectan has the ability to mitigate the damaging effects of ionizing radiation on the gastrointestinal system and shows significant survival benefits suited to the Defense Dept.'s requirements. Brozak says the contract could go as high as $200 million based on similar awards. Walter Schenker of Titan Capital Management, which owns shares, says Protectan has shown effectiveness against radiation when applied two hours prior to exposure or up to eight hours after”	Love	June 22, 2007
the_market_today	CBLI Gaining Upward Share Price Momentum, as Investors are Responding Tomorrow, June 22nd is a key date. It was previously reported that CBLI will join the Russell Microcap Index when Russell Investment Group reconstitutes its family of U.S. indexes on June 22nd. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets currently are benchmarked to them. Russell Investment Group aims to improve financial security for people by providing strategic advice, world-class implementation, state-of-the-art performance benchmarks, and a range of institutional-quality investment products.	Love	June 21, 2007
the_market_today	Curaxin CBLC102 Holds Promise for the Treatment of Prostate Cancer Curaxin CBLC102 is a safe, oral drug used in the past to treat malaria that demonstrates efficacy in vitro, in animal models, and in live tumors removed from patients. Initial test results indicate that CBLC102 can be effective against a number of malignancies, including hormone refractory prostate cancer, renal cell carcinoma (a highly fatal form of kidney cancer), and soft-tissue sarcoma. The FDA permitted Cleveland BioLabs to advance directly to Phase II studies, based on CBLC102's historic safety profile. The Company has a "method of use" patent application pending on Curaxin CBLC102. Last December, the Company began its Phase II efficacy study for Curaxin CBLC102 in advanced, hormone-refractory (androgen independent) prostate cancer at the Cleveland Clinic and Case Western Reserve University Hospital	Love	June 20, 2007
the_market_today	Shares Continue on Recent Upward Trend Up an Additional 2 Percent Today The recent Bone Marrow Stem Cell Transplantation Study suggests multiple potential uses for CBLB612. Blood from healthy mice treated by Protectan CBLB612 was transplanted into mice that received a lethal dose of radiation that killed hematopoietic (bone marrow/blood production) stem cells. A small amount of blood from the CBLB612 treated mice successfully rescued the mice with radiation-induced bone marrow stem cell deficiency. 100% of the deficient mice transplanted with blood from CBLB612 treated mice survived past the 60-day mark, while 85% of the untreated deficient mice died within the first three weeks of the experiment. The 60- day mark is considered to be the critical point in defining the presence of long-term adult bone marrow stem cells, which are capable of completely restoring lost or injured bone marrow function. The rescuing effect of the peripheral blood of the treated mice was equivalent to that of conventional bone marrow transplantation. Cleveland BioLabs President and Chief Executive Officer, Michael Fonstein, Ph.D., commented, "We are very excited about the results we have achieved to date in our studies of Protectan CBLB612 as an effective producer of long-term adult bone marrow stem cells in peripheral blood. The transplant study in particular, has advanced our research into clinical applications and suggests multiple potential uses within the field of regenerative medicine."	Love	June 19, 2007
the_market_today	Department of Defense Contracts May Hold the Key In March, Cleveland BioLabs received a contract from the Defense Threat Reduction Agency (DTRA) of the Department of Defense (DoD) to fund "development leading to the acquisition" of Protectan CBLB502, in collaboration with the Armed Forces Radiobiology Research Institute (AFRRI), which has also received significant independent funding for work on Protectan CBLB502. In April, Cleveland BioLabs, Inc. , responded to an additional Request for Proposal (RFP) issued in March 2007, by The Department of Defense (DoD) for the Advanced Development of Medical Radiation Countermeasures (MRC) to treat gastrointestinal effects of acute radiation syndrome (ARS). It is expected that the RFP may be awarded later in the year. The objective of the RFP is to develop a post-exposure Medical Radiation Countermeasure through approval/licensure with the U.S. Food and Drug Administration (FDA) and procure quantities sufficient to achieve Initial Operational Capability (IOC). A range of 50,000 to 500,000 doses was specified. The RFP award would provide funding for development of the countermeasure through FDA approval, as well as a commitment to purchase, thereafter.	Love	June 18, 2007
the_market_today	Listing in Russell Microcap™ Index is Very Good News Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets currently are benchmarked to them. Annual reconstitution of Russell indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization to create the Russell 3000® Index and Russell Microcap. With more than $200 billion in assets under management, Russell serves individual, institutional and advisor clients in more than 40 countries. Russell provides access to some of the world's best money managers. It helps investors put this access to work in corporate defined benefit and defined contribution plans, and in the life savings of individual investors.	Love	June 13, 2007
the_market_today	The Shares Rebounded Today, with Solid Volume; as Company Reports Investment Visibility CBLI reported that it will join the Russell Microcap(TM) Index when Russell Investment Group reconstitutes its family of U.S. indexes on June 22, according to a preliminary list of additions posted Friday on www.russell.com. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. Dr. Michael Fonstein, Chief Executive Officer and President of Cleveland BioLabs, stated, "Our addition to the Index is reflective of the Company's significant growth and development since our IPO last year. We look forward to increased visibility resulting from our inclusion." Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets currently are benchmarked to them.	Love	June 12, 2007
the_market_today	Cancer Stocks Represent an Important and Viable Niche Sector Analysts noted that many Cancer related stocks advanced in early June, as presentations began at the American Society of Clinical Oncology which was meeting in Chicago. CBLI is clearly one emerging firm, with three key products in development, that hold promise. Cleveland BioLabs recently announced the results of a study of the efficacy of Protectan CBLB612, one of its radiation protectors, in an animal bone marrow stem cell transplantation model. Peripheral blood from CBLB612-treated donors rescued 100% of lethally irradiated mice from bone marrow deficiency. The rescuing effect of the peripheral blood of the treated mice was equivalent to that of conventional bone marrow transplantation. The Company has two lead compounds in late stages of development. Curaxin CBLC102 is an orally administered small molecule designed to kill tumor cells by simultaneously targeting two key regulators of apoptosis. The Company has an ongoing Phase II trial with CBLC102 in hormone refractory prostate cancer. Cleveland BioLabs' other lead compound, Protectan CBLB502, is a modified protein of a microbe that protects cells from regulated cell death. The Company recently submitted CBLB502 to the Department of Defense in response to a Request for Proposal (RFP) for medical radiation countermeasures to treat gastrointestinal effects of acute radiation syndrome. The RFP award would provide funding for development of the countermeasure through FDA approval, as well as a commitment to purchase up to 500,000 doses, thereafter.	Love	June 11, 2007
the_market_today	Study Continues to Show Efficacy Protectan CBLB612 Contines to Show Efficacy in the Field of Stem Cell Transplantation and Regenerative Medicine "We are very excited about the results we have achieved to date in our studies of Protectan CBLB612 as an effective producer of long-term adult bone marrow stem cells in peripheral blood. The transplant study in particular, has advanced our research into clinical applications and suggests multiple potential uses within the field of regenerative medicine." Adult hematological bone marrow stem cell transplantation is currently used for hematological disorders (malignant and non-malignant), as well as some non-hematological diseases, such as breast cancer, testicular cancer, neuroblastoma, ovarian cancer, Severe Combined Immune Deficiency (SCID), Wiskott-Aldrich syndrome, and Chediak-Higashi syndrome. Administration of Protectan CBLB612 increases the level of a number of cytokines known to stimulate blood regeneration. This compares to the current clinical practice of administering a single purified cytokine, such as G-CSF (Neupogen®, Granocyte®, Neulasta®). Protectan CBLB612 stimulates production of adult bone marrow stem cells through multiple mechanisms, making it potentially more effective than currently used clinical protocols. In addition, Protectan CBLB612 could be used in treating those individuals that do not respond to G-CSF. In addition to efficacy in stimulation and mobilization of stem cells, Protectan CBLB612 has demonstrated both radiation protection and mitigation properties over a very broad time window of use. In animal experiments, Protectan CBLB612 has produced complete and sustained recovery of the blood production system following lethal doses of radiation.	Love	June 09, 2007
the_market_today	Shares have been Trending Higher Lately Shares Up 3.27% Today, as the Company Continues its Important Work. Recently, I read that CBLI selected the InSpire reporting tool from PharmaVigilant for its upcoming Phase II trial. "We chose InSpire because it provides us unprecedented access to our data, not only during the trial but throughout our development program. The I- Warehouse reporting tool offers us the access to our data that we need during our early stages of development." said John Gordon, Director Clinical Development for Cleveland Biolabs. I-Warehouse includes access to the InSpire Reporting Tool, the only ad hoc reporting tool in the industry that provides Sponsors with the ability to query their data both within and across trials. With the proprietary Health Information Protection Key (HIP Key), Sponsors can view their patients' data across multiple trials and programs without affecting participant confidentiality. PharmaVigilant offers unique solutions to address the complexities of global clinical research. The Company focuses on Phase 2-4 clinical trials, registries and other post-marketing studies. The InSpire solution supports over 200,000 patients in 14 countries in North America and Europe, and incorporates the latest single platform,	Love	June 07, 2007
the_market_today	CBLB502 is the Company’s Radiation Antidote Cleveland BioLabs Protectan CBLB502 Demonstrated Strong Survival Benefits as a Mitigator against Radiation-Induced Damage in Study CBLB502 is the first compound to provide protection from both gastrointestinal and hematopoietic radiation-induced damage when administrated before or after irradiation. Moreover, mitigation shown in two animal species opens much broader potential markets for CBLB502's use as a radiation antidote." The Company is submitting Protectan CBLB502 to the Department of Defense (DoD) in response to a recently published Request for Proposal (RFP) for medical radiation countermeasures to treat gastrointestinal effects of acute radiation syndrome. The RFP award would provide funding for development of the countermeasure through FDA approval, as well as a commitment to purchase up to 500,000 doses, thereafter. Protectan CBLB502 is undergoing an accelerated development program under the FDA two-animal rule, which requires the Company to show efficacy in two animal species and only safety in humans. Cleveland BioLabs is in the process of completing Good Manufacturing Practices compliant (cGMP) manufacturing of Protectan CBLB502 and plans to submit an Investigational New Drug (IND) application for a human safety study later this year.	Love	June 06, 2007